Skip to main content
Journal cover image

Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.

Publication ,  Journal Article
Austin, SL; Chiou, A; Sun, B; Case, LE; Govendrageloo, K; Hansen, P; Kishnani, PS
Published in: Mol Genet Metab
2017

OBJECTIVE: PRKAG2 syndrome, an autosomal dominant disorder, is characterized by severe infantile hypertrophic cardiomyopathy and heart rhythm disturbances to cases with a later presentation and a spectrum of manifestations including cardiac manifestations, myopathy and seizures. The cardiac features of PRKAG2 resemble the cardiac manifestations of Pompe disease. We present a patient who was initially diagnosed with Pompe disease and treated with alglucosidase-alfa enzyme replacement therapy (ERT); however, he was eventually diagnosed to carrying a PRKAG2 pathogenic gene mutation; he did not have Pompe disease instead he was a carrier for the common adult leaky splice site mutation in the GAA gene. CASE REPORT: At 2.5months, the patient had hypotonia/generalized muscle weakness, a diagnosis of non-classic infantile Pompe disease was made based on low acid alpha-glucosidase activity and the patient started on ERT at 11months. However, 1month later, the patient began to have seizures. As the patient's medical history was somewhat unusual for infantile Pompe disease, further evaluation was initiated and included a glycogen storage disease sequencing panel which showed that the patient had a pathogenic mutation in PRKAG2 which had been reported previously. ERT was discontinued and patient had a progression of motor deficits. ERT was reinitiated by the treating physician, and a clinical benefit was noted. CONCLUSION: This report outlines the benefits of ERT with alglucosidase alfa in a patient with PRKAG2 syndrome, the decline in his condition when the ERT infusions were discontinued, and the significant positive response when ERT was reinitiated.

Duke Scholars

Published In

Mol Genet Metab

DOI

EISSN

1096-7206

Publication Date

2017

Volume

120

Issue

1-2

Start / End Page

96 / 100

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Treatment Outcome
  • Mutation
  • Male
  • Humans
  • Glycogen Storage Disease
  • Genetics & Heredity
  • Enzyme Replacement Therapy
  • Child, Preschool
  • AMP-Activated Protein Kinases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Austin, S. L., Chiou, A., Sun, B., Case, L. E., Govendrageloo, K., Hansen, P., & Kishnani, P. S. (2017). Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Mol Genet Metab, 120(1–2), 96–100. https://doi.org/10.1016/j.ymgme.2016.09.006
Austin, Stephanie L., Andrew Chiou, Baodong Sun, Laura E. Case, Kenny Govendrageloo, Perrin Hansen, and Priya S. Kishnani. “Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.Mol Genet Metab 120, no. 1–2 (2017): 96–100. https://doi.org/10.1016/j.ymgme.2016.09.006.
Austin SL, Chiou A, Sun B, Case LE, Govendrageloo K, Hansen P, et al. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Mol Genet Metab. 2017;120(1–2):96–100.
Austin, Stephanie L., et al. “Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.Mol Genet Metab, vol. 120, no. 1–2, 2017, pp. 96–100. Pubmed, doi:10.1016/j.ymgme.2016.09.006.
Austin SL, Chiou A, Sun B, Case LE, Govendrageloo K, Hansen P, Kishnani PS. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Mol Genet Metab. 2017;120(1–2):96–100.
Journal cover image

Published In

Mol Genet Metab

DOI

EISSN

1096-7206

Publication Date

2017

Volume

120

Issue

1-2

Start / End Page

96 / 100

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Treatment Outcome
  • Mutation
  • Male
  • Humans
  • Glycogen Storage Disease
  • Genetics & Heredity
  • Enzyme Replacement Therapy
  • Child, Preschool
  • AMP-Activated Protein Kinases